Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat
Eisai and Biogen announced the decision to discontinue the Phase III clinical studies on the investigational oral BACE inhibitor elenbecestat in patients with early Alzheimer's disease. The decision is based on the results of a safety review conducted by the DSMB. September 13, 2019